Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U04 Substudy 04B in first-line advanced urothelial carcinoma
NL-OMON53800Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of enfortumab vedotin, favezelimab + pembrolizumab, vibostolimab + pembrolizumab and pembrolizumab in transitional cell carcinoma (TCC) and bladder cancer (3 arms), sponsored by Merck & Co. Primary endpoints: Objective response rate, Safety and tolerability and 1 more. Started Jun 2023; status: recruiting.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON53800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53800.